Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Abstract: An abuse deterrent pharmaceutical composition including a drug susceptible to abuse, a first acid soluble ingredient, a first buffering ingredient, and a delayed release buffering component.

Abstract: An abuse deterrent pharmaceutical composition including a drug susceptible to abuse, a first acid soluble ingredient, a first buffering ingredient, and a delayed release buffering component.

Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Abstract: An abuse deterrent pharmaceutical composition including a drug susceptible to abuse, a first acid soluble ingredient, a first buffering ingredient, and a delayed release buffering component.

Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Abstract: Systems and methods include receiving a request from a Relying Party to verify an attribute that is one or more of an identity and a credential of a user; notifying the user of the request and receiving self-asserted attributes by the user; obtaining Attribute Provider attributes from an Attribute Provider based on the self-asserted attributes; determining an answer to the request based on the self-asserted attributes and the Attribute Provider attributes; and providing the answer to the Relying Party. The systems and methods can further include receiving a response from the user including how much data to release to the Relying Party, wherein the answer is constrained based on the response to one of a yes/no answer, a range, and a detailed response.

Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Abstract: A computer-implemented method for managing a personal data store is described for binding one or more identities of different types associated with a user. The computer-implemented method is implemented in a trust system including one or more processing devices communicatively coupled to a network. The computer-implemented method includes receiving one or more self-asserted first attributes by the user and second attributes asserted by an Attribute Provider; utilizing one or more of the first attributes and the second attributes as inputs to obtain and/or produce one or more cryptographically signed attributes signed by an associated Attribute Provider; storing the first attributes, the second attributes, and the one or more cryptographically signed attributes in a personal data store associated with the user; and utilizing one or more of the first attributes, the second attributes, and the one or more cryptographically signed attributes to respond to a request from a Relying Party.

Abstract: A method for preparing solid materials is described. One aspect of the method includes the steps of (a) providing a feedstock comprising an organic material(s) in a solvent system containing a non-solvent for the organic material at an elevated temperature and/or pressure above ambient conditions, (b) distributing the feedstock into either droplets or a film, and (d) evaporating the solvent system from the feedstock.

Abstract: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.

Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Abstract: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.

Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Abstract: A computer-implemented method for managing a personal data store is described for binding one or more identities of different types associated with a user. The computer-implemented method is implemented in a trust system including one or more processing devices communicatively coupled to a network. The computer-implemented method includes receiving one or more self-asserted first attributes by the user and second attributes asserted by an Attribute Provider; utilizing one or more of the first attributes and the second attributes as inputs to obtain and/or produce one or more cryptographically signed attributes signed by an associated Attribute Provider; storing the first attributes, the second attributes, and the one or more cryptographically signed attributes in a personal data store associated with the user; and utilizing one or more of the first attributes, the second attributes, and the one or more cryptographically signed attributes to respond to a request from a Relying Party.

Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.

Abstract: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.